


Study finds that a 100-year-old treatment inhibits COVID-19 infection

July 24 2023, by Katie Malatino



Suramin interacts with SARS-CoV-2 RBD variants for inhibiting SARS-CoV-2 cell entry. **a** Structure of suramin and proposed targets. Figure created with Chemdraw and Biorender.com. **b** SPR assay used to determine the binding affinity of suramin with immobilized SARS-CoV-2 variant RBDs (wild type (WT), Delta, and Omicron) on-chip (left panel). Equilibrium binding constants of suramin to RBD of different variants (right panel). **c** Sensorgrams for binding

of suramin to SARS-CoV-2 variants. Various concentrations of suramin (6.25–200 μ M in PBS) were flowed over an RBD chip containing WT, Delta, and Omicron variants on different flow cells. For these experiments $n = 3$ biological replicates. Statistical significance was determined using a student's t-test with $p > 0.05 = \text{ns}$, $*p$

Citation: Study finds that a 100-year-old treatment inhibits COVID-19 infection (2023, July 24) retrieved 13 May 2024 from <https://medicalxpress.com/news/2023-07-year-old-treatment-inhibits-covid-infection.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.